Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: A phase II study in stage IIIB-IV non-small cell lung cancer

E. Baldini, C. Tibaldi, A. Chella, C. A. Angeletti, A. Romanini, A. Andrei, R. Algeri, G. Silvano, P. F. Conte

Research output: Contribution to journalArticlepeer-review

Abstract

Forty-five stage IIIB-IV non-small cell lung cancer (NSCLC) patients entered a phase II study designed to evaluate the toxicity and the activity of a combination chemotherapy regimen consisting of vinorelbine (25 mg/m2 days 1 and 8), ifosfamide (3 g/m2 day 1 with uroprotective mesna), and cisplatin (80 mg/m2 day 1). The regimen, VIP, was administered on an outpatient basis every 3 weeks. White blood cell counts were checked weekly, and granulocyte colony-stimulating factor was administered in case of grade 4 neutropenia lasting for more than 48 hours. Leukopenia was the most frequent toxicity, with grades 3 and 4 neutropenia reported in 25% of cycles and 11 episodes of febrile neutropenia recorded in 175 evaluable courses. The combination of vinorelbine and cisplatin did not result in additive neurotoxicity: only five patients experienced grade 2 neurotoxicity after six courses of treatment. Thirty-five patients were evaluable for response. Twenty partial responses (57%) and one complete response (2.8%) were observed, for an overall response rate of 60% (95% confidence interval, 42% to 76%). The median time to progression, measured from the start of treatment, was 7 months (range, 1 to 18+), and median survival for the whole group was 12 months (range, 1 to 18+). VIP is a well-tolerated regimen and shows interesting activity in advanced NSCLC.

Original languageEnglish
Pages (from-to)12-15
Number of pages4
JournalSeminars in Oncology
Volume21
Issue number3 SUPPL. 4
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: A phase II study in stage IIIB-IV non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this